Syntara CEO Gary Phillips hosted an investor webinar to discuss recent updates, including the positive FDA feedback supporting the planned Phase 2b trial of amsulostat in myelofibrosis, as well as the capital raising undertaken by the Company.
Share
Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.
